Fabio Amorosino takes over as CEO of Biolab Farmacêutica and partners become board members
Biolab Farmacêutica will take another step in its corporate governance program. As of October 1st, shareholders Cleiton de Castro Marques, CEO, Paulo de Castro Marques, COO and Dante Alario Jr, CSO, will leave their positions to become members of the board of directors. Fabio Amorosino, currently a board member at Biolab, will take over as CEO of the company.
"We are planning Biolab's future very carefully. This process began seven years ago, when we hired McKinsey to help us define the governance model. After a series of internal advances, which included preparing the second generation - who are already in leadership positions - and setting up the board with independent members, we are now moving forward with Fabio Amorosino as CEO," says Cleiton Marques.
Cleiton points out that all of Biolab's moves are aimed at perpetuating the company and accelerating its growth rate, which has been above the average for the healthcare market in recent years. Operating in human and animal health, Biolab had revenues of R$ 2.4 billion in 2023 and estimates revenues of close to R$ 3 billion in 2024.
In this sense, he emphasizes that there is no rush in the transition. "This process will be gradual. We are confident that we will succeed in appointing a competent professional to the helm of the company, who has vast experience, including with family groups, and who has already been on our board for two years."
Fabio Amorosino is a business administrator by training and has a long career in large financial organizations, including more than two decades at Grupo Alfa, where he was CEO for 15 years.
"As a board member, I actively experience Biolab's routines. This period has allowed me to learn more about the company's segment, infrastructure, business model and culture. This close contact with Biolab, the board and the healthcare world will certainly contribute to the success of this new challenge and make the transition process a natural one," says Fabio Amorosino.
About Biolab
Promoting a future with a better quality of life requires a tireless search for safe and innovative treatments. With this mission in mind, Biolab, a Brazilian pharmaceutical company founded in 1997 and with an international presence, invests in research and partnerships to overcome the growing challenges of human and animal health.
With around 4,000 employees and the 4th largest sales force in Brazil, Biolab is among the largest pharmaceutical companies in the country, operating in various specialties, such as dermatology, gynecology, orthopedics, gastroenterology, pediatrics, clinical medicine and the central nervous system, as well as being a leader in cardiology. The Biolab Genéricos, Avert Humana and Avert Biolab Saúde Animal business units contribute to a portfolio of more than 500 products.
Biolab is constantly growing. There are three production units, as well as a modern manufacturing complex under construction in Pouso Alegre (MG), the result of investments of R$ 1 billion, which will increase the company's manufacturing capacity fivefold. And it doesn't stop there: in Canada it is the first Brazilian pharmaceutical company with a Research Center and it acquired the company Exzell Pharma to expand its borders.
Long live evolution!
Find out more at www.biolabfarma.com.br and on social media: Instagram, Facebook and Linkedin.